Volume 23, Issue 2 - Regulatory Writing Basics

Did minor flaws in a new drug reveal major flaws in company publication practices?

Author: Karl Gruber

Abstract

Download the full article

References

1. Adam SS, McDuffie JR, Ortel TL, Williams JW Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012;157(11):796–807.
2. Study of Drug for Blood Clots Caused a Stir, Records Show. The New York Times [cited 2014 Feb 5]. Available from: http://www.nytimes.com/2014/02/06/business/study-of-blood-clot-drug-pradaxa-unnerved-its-maker-documents-suggest.html
3. Unsealed Court Documents in Pradaxa Case. Available from: http://www.nytimes.com/interactive/2014/02/05/business/pradaxa-doc-viewer.html?action=click&contentCollection=Business%20Day&module=RelatedCoverage&region=Marginalia&pgtype=article&_r=1
4. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013;145(1):105–12.
5. EMA. Pradaxa. dabigatran etexilate. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp&mid=WC0b01ac058001d124
6. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients in the RE-LY trial. J Am Coll Cardiol 2014;63(4):321–328.